Selective PRMT5 inhibition suppresses inflammatory T cell responses and autoimmunity.

被引：0
|
作者：
Webb, Lindsay M.
Savardekar, Himanshu
Jablonski, Kyle A.
Amici, Stephanie A.
Panfil, Amanda
Li, Linsen
Green, Patrick L.
Li, Chenglong
Baiocchi, Robert A.
Guerau-De-Arellano, Mireia
机构：
来源：
JOURNAL OF IMMUNOLOGY | 2017年 / 198卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
156.12
引用
收藏
页数：4
相关论文
共 50 条
  • [31] PRMT5 inhibition as a therapeutic strategy for KRAS mutant CRC: downstream mediators of the PRMT5-KRAS crosstalk
    Shifteh, David
    Sapir, Tzuriel
    Pahmer, Moshe
    Goel, Sanjay
    Maitra, Radhashree
    CANCER RESEARCH, 2023, 83 (07)
  • [32] PRMT5-selective inhibitors suppress inflammatory T cell responses and experimental autoimmune encephalomyelitis (vol 198, pg 1439, 2017)
    Webb, L. M.
    Amici, S. A.
    Jablonski, K. A.
    Savardekar, H.
    Panfil, A. R.
    Li, L.
    Zhou, W.
    Peine, K.
    Karkhanis, V.
    Bachelder, E. M.
    Ainslie, K. M.
    Green, P. L.
    Li, C.
    Baiocchi, R. A.
    Guerau-de-Arellano, M.
    JOURNAL OF IMMUNOLOGY, 2017, 199 (08): : 3004 - 3004
  • [33] Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors
    Lin, Hong
    Wang, Min
    Zhang, Yang W.
    Tong, Shuilong
    Leal, Raul A.
    Shetty, Rupa
    Vaddi, Kris
    Luengo, Juan I.
    ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (07): : 1033 - 1038
  • [34] Arginine methylation drives inflammatory T cell responses and autoimmunity
    Webb, Lindsay M.
    Savardekar, Himanshu
    Jablonski, Kyle A.
    Amici, Stephanie A.
    Li, Linsen
    Li, Chenglong
    Baiocchi, Robert A.
    Guerau-De-Arellano, Mireia
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [35] A live cell PRMT5 NanoBRET Target Engagement Assay querying competitive and uncompetitive modes of inhibition
    Michaud, Ani
    Rothweiler, Elisabeth
    Corona, Cesear
    Beck, Michael
    Wilkinson, Jennifer
    Vasta, James
    Huber, Kilian
    Robers, Matthew
    CANCER RESEARCH, 2024, 84 (06)
  • [36] Selective modulation of T-cell responses in autoimmunity and cancer
    Ottenhoff, THM
    IMMUNOLOGY TODAY, 1996, 17 (02): : 54 - 55
  • [37] Inhibition of PRMT5 Increases Sensitivity to BH3 Mimetics in Aggressive B Cell Malignancies
    Zhu, Fen
    Ryan, Christine E.
    Hackett, Liam R.
    Collins, Mary C.
    Chong, Stephen Jun Fei
    Davids, Matthew S.
    BLOOD, 2022, 140 : 8842 - 8843
  • [38] PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma
    Brown-Burke, Fiona
    Hwang, Inah
    Sloan, Shelby
    Hinterschied, Claire
    Helmig-Mason, Jobeth
    Long, Mackenzie
    Chan, Wing Keung
    Prouty, Alexander
    Chung, Ji-Hyun
    Zhang, Yang
    Singh, Satishkumar
    Youssef, Youssef
    Bhagwat, Neha
    Chen, Zhengming
    Chen-Kiang, Selina
    Di Liberto, Maurizio
    Elemento, Olivier
    Sehgal, Lalit
    Alinari, Lapo
    Vaddi, Kris
    Scherle, Peggy
    Lapalombella, Rosa
    Paik, Jihye
    Baiocchi, Robert A.
    BLOOD ADVANCES, 2023, 7 (20) : 6211 - 6224
  • [39] A live cell PRMT5 NanoBRETT target engagement assay querying competitive and uncompetitive modes of inhibition
    Teske, Kelly A.
    Michaud, Ani
    Rothweiler, Elisabeth
    Corona, Cesear
    Hoffman, Kaitlin Dunn
    Wilkinson, Jennifer
    Beck, Michael
    Vasta, James
    Huber, Kilian
    Robers, Matthew
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (06)
  • [40] Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel
    Mueller, Helen S.
    Fowler, Colin E.
    Dalin, Simona
    Moiso, Enrico
    Udomlumleart, Tee
    Garg, Salil
    Hemann, Michael T.
    Lees, Jacqueline A.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2021, 118 (34)
12345